MDS 2026 — Parkinson's Disease Clinical Advances

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

The MDS 2026 congress featured comprehensive coverage of [Parkinson's disease](/diseases/parkinsons-disease-disease) research and clinical advances. This page captures key clinical findings presented at the congress, focusing on motor complications, non-motor symptoms, biomarkers, and emerging therapeutics["@mds2026"].

> Note: This page will be updated with specific abstracts and presentations as they become available from the congress proceedings.

Motor Complications

Levodopa-Induced Dyskinesia

Congress: Movement Disorder Society (MDS) International Congress 2026 Dates: October 4-8, 2026 Location: Seoul, Korea — COEX Convention and Exhibition Center Theme: Understanding Aging in Movement Disorders

Overview

The MDS 2026 congress featured comprehensive coverage of [Parkinson's disease](/diseases/parkinsons-disease-disease) research and clinical advances. This page captures key clinical findings presented at the congress, focusing on motor complications, non-motor symptoms, biomarkers, and emerging therapeutics["@mds2026"].

> Note: This page will be updated with specific abstracts and presentations as they become available from the congress proceedings.

Motor Complications

Levodopa-Induced Dyskinesia

Advances in understanding and managing [levodopa-induced dyskinesia](/diseases/parkinsons-disease-disease) (LID) remain a critical focus:

• Mechanistic Insights: New data on glutamate receptor modulation and dopamine receptor desensitization
• Dopamine Agonist Strategies: Long-acting agonists showing promise in reducing dyskinesia
• Deep Brain Stimulation: Refined targeting protocols for optimal motor outcomes
• Gene Therapy Approaches: AAV-based GAD and AADC gene therapy results

Motor Fluctuations and Wearing-Off

Management strategies for motor fluctuations:

• Continuous Dopaminergic Delivery: Intravenous and subcutaneous levodopa formulations
• Apomorphine Infusion: Long-term efficacy and safety data
• Duodenal Levodopa: Real-world outcomes from international cohorts

Gait and Balance Disorders

Advanced therapies for postural instability and gait difficulty:

• Freezing of Gait: Novel pharmacological and neuromodulation approaches
• Rehabilitation Technologies: Virtual reality and cueing device trials
• Cerebellar Stimulation: Targeting the cerebellum for gait improvement

Non-Motor Symptoms

Cognitive Impairment and Dementia

Addressing cognitive decline in PD:

• DLB Overlap: Distinguishing features and treatment implications
• Cholinergic Therapeutics: Cholinesterase inhibitors in PD dementia
• Neuroimaging Biomarkers: PET and MRI markers for cognitive progression
• Early Intervention Strategies: Trials in prodromal cognitive impairment

Neuropsychiatric Features

Managing depression, psychosis, and impulse control:

• Depression: Esketamine and novel serotonergic approaches
• Psychosis: Pimavanserin long-term data and新一代 antipsychotics
• Impulse Control Disorders: Behavioral and pharmacological interventions

Sleep Disorders

Advances in PD sleep disturbance management:

• REM Sleep Behavior Disorder: Neuroprotective strategies in prodromal PD
• Insomnia: Dual orexin receptor antagonists
• Excessive Daytime Sleepiness: Modafinil and wake-promoting agents

Autonomic Dysfunction

Treatment of autonomic failures in PD:

• Orthostatic Hypotension: Midodrine, droxidopa, and pyridostigmine data
• Gastrointestinal Dysmotility: Prokinetic agents and microbiome modulation
• Urinary Dysfunction: Antimuscarinics and beta-3 agonists

Biomarkers and Diagnostics

Alpha-Synuclein Biomarkers

Critical advances in [alpha-synuclein](/proteins/alpha-synuclein) detection:

• Seed Amplification Assays: CSF and skin biopsy validation
• PET Tracers: Novel ligands for alpha-synuclein imaging
• Blood-Based Biomarkers: NFL and alpha-synuclein PTMs

Genetic and Molecular Markers

PD risk stratification:

• LRRK2 Pharmacodynamics: Target engagement biomarkers
• GBA Variants: Enzyme activity as therapeutic response marker
• Polygenic Risk Scores: Clinical utility studies

Digital Biomarkers

Wearable and digital health technologies:

• Movement Analysis: Smartphone-based tapping and gait analysis
• Voice Analysis: Speech features for progression monitoring
• Continuous Monitoring: Home-based sensor systems

Emerging Therapeutics

Disease-Modifying Therapies

Alpha-Synuclein-Targeted Approaches

• Immunotherapies: Active and passive vaccination programs (ABBV-0805, PRX004)
• Oligomer Stabilizers: Small molecules preventing aggregation
• Autophagy Inducers: Trehalose and rapamycin analogs

LRRK2 Inhibitors

• DNL151/DNL274: AbbVie/Genentech LRRK2 inhibitor program
• BIIB122: Biogen's LRRK2 inhibitor
• Target Engagement: PET ligand validation for CNS penetration

Neuroprotective Strategies

• Inosine Supplementation: Urate elevation neuroprotection
• CoQ10 and Mitochondrial Function: Phase 3 results
• Anti-apoptotic Agents: Bcl-2 family modulators

Cell and Gene Therapy

• Stem Cell-derived Dopaminergic Neurons: Clinical-grade cell production
• AAV-GAD: Glutamic acid decarboxylase gene therapy
• AADC Gene Therapy: Long-term motor outcome data
• LRRK2 Gene Editing: CRISPR-based approaches

GLP-1 Receptor Agonists

The [GLP-1 receptor agonist](/therapeutics/glp-1-receptor-agonists-parkinsons) class continues to show promise:

• Exenatide: Phase 3 trial design and recruitment
• Liraglutide: Motor and non-motor outcome data
• Semaglutide: Phase 2 results in early PD

Anti-Inflammatory Approaches

Targeting neuroinflammation in PD:

• TREM2 Modulation: Microglial activation modulation
• Complement Inhibition: C1q and C3 targeting strategies
• Minocycline: Long-term neuroprotection data

Clinical Trial Pipeline

Active Phase 3 Trials in PD

| Agent | Mechanism | Sponsor | Status |
|-------|-----------|---------|--------|
| ABBV-0805 | Alpha-synuclein antibody | AbbVie | Phase 2/3 |
| BIIB122 | LRRK2 inhibitor | Biogen | Phase 2b |
| Exenatide | GLP-1 RA | Various | Phase 3 |
| AAV-GAD | Gene therapy | Various | Phase 2 |
| Inosine | Urate elevation | Various | Phase 3 |

Upcoming Trial Readouts

Expected results from MDS 2026 presentations include:

• Long-term follow-up of gene therapy trials
• Biomarker correlates from disease-modification studies
• Real-world evidence from approved therapies

Related Pages

• [MDS 2026](/events/mds-2026) — Main congress page](/events)
• [Parkinson's Disease](/diseases/parkinsons-disease) — Comprehensive PD overview](/proteins/parkin)
• [Parkinson's Disease Dementia](/diseases/parkinson-disease-dementia) — Cognitive complications](/proteins/parkin)
• [Alpha-synuclein Protein](/proteins/alpha-synuclein)](/proteins)
• [LRRK2 Gene](/genes/lrrk2)](/genes)
• [GLP-1 Receptor Agonists in Parkinson's](/therapeutics/glp-1-receptor-agonists-parkinsons)](/therapeutics)
• [CoQ10 for Parkinson's](/therapeutics/coq10-parkinsons)](/therapeutics)
• [Vagus Nerve Stimulation in PD](/therapeutics/vagus-nerve-stimulation-parkinsons-disease)

External Links

• [MDS Congress](https://www.mdscongress.org)
• [PubMed - Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/)](/proteins/parkin)
• [ClinicalTrials.gov - Parkinson's](https://clinicaltrials.gov/)

References